SNY CHMP opinion: Thursday, July 23, 2026
Variation type II · Dupixent · Update of section 5.1 of the SmPC in order to update clinical efficacy information based on final results from the phase 4 study LPS15834 (VESTIGE); this is a 24-week multicenter, randomized, double-blind, placebo-controlled, parallel group global phase IV study evalua
Dates are sourced from official registries and filings and can change — estimated dates (marked ~) slip routinely. This page updates automatically when the source registry moves the date. Research information only, not investment advice.
Every date on this page is free — forever.
A free account adds the interactive calendar with US/EU filters and watchlists. Investor (€19/mo) adds Impact Forecasts on each event, date-slip tracking and calendar sync (Google/Apple/Outlook). Pro adds the full analytics stack.